Biobanque Québécoise Pédiatrique de Cancers et de Greffes de cellules hématopoïétiques, Canada
Objective: Our translational research program is geared toward advancing knowledge across the continuum of pediatric cancer care spanning prevention through diagnosis/prognosis, to long-term survival. One key component of this research program is the access to a state-of-the-art biobank. Our biobank is a resource that houses clinical data and biological samples from various patient-based study cohorts. We have been recruiting childhood Acute Lymphoblastic Leukemia (cALL) patients diagnosed at the Sainte-Justine Hospital since 1994 in the Quebec childhood Acute Lymphoblastic Leukemia (QcALL) cohort. Since then, we added patients from the childhood ALL survivor PETALE cohort; patients who underwent bone marrow transplant (BaCH); patients with solid tumours (TuQue); patients from the Personalized Targeted Therapy in Refractory/Relapsed Cancer in Childhood (TRICEPS) study; and patients from the omic-based translational research strategy for newly diagnosed cancers (Signature) cohort. QcALL cohort: we collect biospecimens at diagnosis, throughout the 2-year treatment course and at relapse or pre-/post-transplant if applicable. The QcALL study is leveraging largescale omic studies geared toward identifying novel (epi)genetic driver events to improve diagnostic and prognostic tools in cALL. PETALE cohort: from 2012 to 2016, we have enrolled patients with a five-year event-free survival period to participate in the PETALE study aimed at identifying the genomic determinants of common treatment related toxicities in cALL survivors. The BaCH study (initiated in 2014) is interested in hematopoietic cell transplantation to better understand the reconstitution mechanisms and improve the outcomes of various types of transplantation. The TRICEPS study, started in January 2014, involves timely (12-week time frame) in-depth characterization of tumor genomes to identify actionable mutations and provide personalized targeted therapy for refractory/relapsed childhood cancer patients. The TuQue study (initiated in 2016) is interested in banking samples from patients diagnosed with a solid tumour, with follow-up samples during a 2-year period. The Signature study, started in 2017, is designed to perform molecular analysis of the newly diagnosed pediatric cancer within the province of Québec with this multicentre study collaborating with the 3 others pediatric centres. To store patient-related clinical, demographic, and genetic information we developed PANDORA 2.0, a Biobank Software System. This in-house solution aims to cover many of the research and operation activities applicable to biological repositories such as inventory tracking, management of patient consent forms, and report generation. All the information contained in PANDORA actively contributes to translational research, bringing patients, researchers and oncologists closer, with the ultimate goal of improving present diagnostic and therapeutic strategies while minimising treatment side effects in pediatric cancers.
|Registered Biobank Name||Biobanque Québécoise Pédiatrique de Cancers et de Greffes de cellules hématopoïétiques|
|Biobank Leader||Thomas Sontag (biobank manager)|
|Email for biobank email@example.com|
|Principal Investigator||Dr Daniel Sinnett|
||Oligo - Collection aimed at supporting several research projects, a research group or a research consortium|